{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-081417","form_type":"8-K","ticker":"ANEB","cik":"0001815974","company_name":"Anebulo Pharmaceuticals, Inc.","filed_at":"2023-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.722457+00:00","generated_at":"2026-06-17T13:16:33.953517+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Anebulo reports positive Phase 2 results for ANEB-001 reversing THC effects","bullets":["Low 10 mg dose of ANEB-001 given 1 hour after THC rapidly reversed psychotropic effects (VAS feeling high p<0.0001).","Pre-specified pooled analysis at 21/30 mg THC showed significance on all primary outcomes (p<0.02 for each).","ANEB-001 was well tolerated; no serious adverse events; mild to moderate THC symptoms observed before dosing.","High-fat meal blunted THC effects, but 10 mg ANEB-001 still significantly reduced VAS feeling high (p=0.003).","Company expects End of Phase 2A meeting with FDA by mid-2023 to discuss path forward."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-081417","json":"https://secwatch.observer/filing/0001193125-23-081417.json","markdown":"https://secwatch.observer/filing/0001193125-23-081417.md","text":"https://secwatch.observer/filing/0001193125-23-081417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815974/000119312523081417/0001193125-23-081417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815974/000119312523081417/d483501d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T13:16:33.953517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}